Clinical Trials Logo
  1. Home
  2. Opioid Withdrawal
  3. NCT04218240

Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal — PGB-LOF  

Opioid Withdrawal Clinical Trial

Official title:
Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM): Can it Increase the Success of Transition to Naltrexone?

Clinical Trial Summary

A phase II double-blind placebo-controlled parallel group clinical trial that will randomize 90 subjects to investigate whether pregabalin (PGB) combined with Lofexidine (LFX) can reduce opioid withdrawal-related subjective effects, and investigate, whether the PGB/LFX combination can increase the proportion of patients with an opioid use disorder (OUD) who complete detoxification and transition to antagonist treatment with extended-release injectable naltrexone (XR-NTX).

Clinical Trial Description

An inpatient detoxification study where pregabalin (PBG) will be given orally at a starting dose of up to 600 mg daily (group 1) tapered to 100 mg daily over 7 days; given with lofexidine (LFX) starting at 2.16 mg daily and declining to 0.72 mg over 7 days. On day 8, subjects are offered an injection of XR-NTX if they provide a urine sample that is negative for opioids and buprenorphine and pass a naloxone challenge. All subjects, regardless of whether or not they receive XR-NTX, will be given a referral and appointment for follow-up treatment when they leave the inpatient detoxification program. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04218240
Study type Interventional
Source University of Pennsylvania
Contact
Status Completed
Phase Phase 2
Start date December 17, 2020
Completion date March 23, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT04080037 - Assessing Opioid Care Practices Using CPV Patient Simulation Modules N/A
Completed NCT04126083 - Lofexidine for Adults Undergoing Lumbar Spine Surgery Phase 4
Completed NCT04140955 - Opioid Tapering After Spine Surgery N/A
Not yet recruiting NCT03813095 - Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction Phase 2
Completed NCT01262092 - Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals Phase 2
Completed NCT04075214 - Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal N/A
Recruiting NCT04325659 - An Innovative Intervention for OUD Treatment Phase 2/Phase 3
Terminated NCT04162145 - BRIDGE Device for Treatment of Opioid Withdrawal N/A
Withdrawn NCT03678792 - Comparison of Three Opioid Detoxification Treatment Regimens Phase 3
Completed NCT04238754 - Oral Cannabidiol for Opioid Withdrawal Phase 1/Phase 2
Recruiting NCT05053503 - Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder N/A
Recruiting NCT05555485 - Understanding the Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic Pain N/A
Active, not recruiting NCT03485430 - Tapering From Long-term Opioid Therapy in Chronic Pain Population. Randomized Controlled Trial With 12 Months Follow up N/A
Recruiting NCT05790551 - Suboxone Dispenser for OUD N/A
Completed NCT03174067 - Buprenorphine in the Emergency Department Phase 4
Completed NCT04731935 - Novel Earpiece for Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal N/A
Completed NCT04470050 - Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal Phase 1/Phase 2
Not yet recruiting NCT06442566 - ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain Phase 1/Phase 2
Recruiting NCT05307458 - Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing
Completed NCT03789214 - Medical Management of Sleep Disturbance During Opioid Tapering Phase 2